Delivery Order SPE2DR25D2104-SPE2DR26F3RLN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,169.95 to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Fycompa 0.5 mg/ml oral suspension in a 340 ml unit. This is a firm fixed-price delivery order with an ultimate completion date of October 27, 2025, and represents a non-competitive set-aside contract. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $7,307.89 to AmerisourceBergen Drug Corp for Fycompa 0.5 mg/ml oral suspension (340ml) on July 18, 2025. This is a firm fixed price delivery order with an ultimate completion date of July 21, 2025, with performance to occur at the contractor's location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Fycompa 2 mg tablets (30-count units) at a ceiling value of $1,423.99. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is set to conclude on December 9, 2025, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,580.41 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Fycompa 8 mg tablets (30-count packages). This is a firm fixed price, competitively awarded delivery order with no set-aside designation and a completion date of July 22, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's place of performance. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,903.46 to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of FYCOMPA 0.5 mg/ml oral suspension (340ml). This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 7, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Fycompa 4 mg tablets (30-count units) on November 7, 2025, with a contract ceiling value of $3,186.63 and completion date of November 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a single line item fulfillment under AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of Fycompa 0.5 mg/ml oral suspension in a 340 ml quantity, with a contract value of $1,930.05. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set to be completed by December 17, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Fycompa (perampanel) is an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Fycompa 8 mg tablets (30-count units) valued at $2,984.13 with firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of December 10, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,081.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Fycompa 8 mg tablets (30-count packaging). This delivery order, which serves as a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA, is scheduled for completion by October 28, 2025, and represents part of the company's ongoing pharmaceutical distribution services to federal healthcare systems. The award was...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for 30 tablets of Fycompa 6 mg, with a contract value of $1,004.34 and an ultimate completion date of November 28, 2025. The award is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is the company's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3RLNDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 15, 2025, for the supply of Fycompa 0.5 mg/ml oral suspension in a 340ml quantity, valued at $10,227.18. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of December 16, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government's military and defense healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As the prime contractor on this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies an extensive range of medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs. The company's selection reflects its demonstrated capability to meet federal procurement requirements through open competition and its established position as a major pharmaceutical distributor serving Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.2k | 12/14/25 |